CFM-4 is primarily used in research settings as a selective modulator of estrogen receptors, particularly showing activity toward ERβ (estrogen receptor beta). Its application lies in studying hormone-related diseases, especially in exploring potential therapeutic pathways for cancers such as prostate and breast cancer. Due to its ability to differentiate between ER subtypes, CFM-4 helps scientists investigate the distinct roles of ERβ in cellular processes without activating ERα, which is associated with unwanted proliferative effects. It is also utilized in developing novel treatments for neurodegenerative diseases and inflammatory conditions, where ERβ activation has shown protective effects. Its use remains confined to preclinical research, aiding in target validation and mechanistic studies.